One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

被引：7

作者：

Ornbjerg, Lykke Midtboll ^{[1
]}

Rugbjerg, Kathrine ^{[1
]}

Georgiadis, Stylianos ^{[1
]}

Rasmussen, Simon Horskjaer ^{[1
]}

Lindstrom, Ulf ^{[2
]}

Pavelka, Karel ^{[3
,4
]}

Yilmaz, Neslihan ^{[5
]}

Favalli, Ennio Giulio ^{[6
]}

Nissen, Michael J. ^{[7
]}

Michelsen, Brigitte ^{[8
,9
,10
]}

Vieira-Sousa, Elsa ^{[11
]}

Jones, Gareth T. ^{[12
]}

Ionescu, Ruxandra ^{[13
]}

Relas, Heikki ^{[14
]}

Sanchez-Piedra, Carlos ^{[15
]}

Tomsic, Matija ^{[16
,17
]}

Geirsson, Arni Jon ^{[18
]}

van der Horst-Bruinsma, Irene ^{[19
]}

Askling, Johan ^{[20
]}

Loft, Anne Gitte ^{[21
,22
]}

Nekvindova, Lucie ^{[4
,23
]}

Direskeneli, Haner ^{[24
]}

Iannone, Florenzo ^{[25
]}

Ciurea, Adrian ^{[26
]}

Fagerli, Karen Minde ^{[8
]}

Santos, Maria Jose ^{[27
]}

Macfarlane, Gary J. ^{[12
]}

Codreanu, Catalin ^{[28
]}

Eklund, Kari ^{[14
]}

Pombo-Suarez, Manuel ^{[29
]}

Rotar, Ziga ^{[16
,17
]}

Gudbjornsson, Bjorn ^{[30
,31
]}

Rusman, Tamara ^{[32
]}

Ostergaard, Mikkel ^{[33
,34
]}

Hetland, Merete Lund ^{[33
,34
]}

机构：

[1] Copenhagen Univ Hosp, Copenhagen Ctr Arthrit Res COPECARE, Ctr Rheumatol & Spine Dis, Ctr Head & Orthopaed, Glostrup, Denmark

[2] Univ Gothenburg, Dept Rheumatol & Inflammat Res, Sahlgrenska Acad, Gothenburg, Sweden

[3] Charles Univ Prague, Fac Med 1, Inst Rheumatol, Prague, Czech Republic

[4] Charles Univ Prague, Fac Med 1, Dept Rheumatol, Prague, Czech Republic

[5] Demiroglu Bilim Univ, Dept Rheumatol, Istanbul, Turkiye

[6] Asst Gaetano Pini CTO Inst, Div Clin Rheumatol, Milan, Italy

[7] Geneva Univ Hosp, Dept Rheumatol, Geneva, Switzerland

[8] Diakonhjemmet Hosp, Dept Rheumatol & Res, Oslo, Norway

[9] Hosp Southern Norway Trust, Dept Med, Div Rheumatol, Kristiansand, Norway

[10] Copenhagen Univ Hosp Glostrup, Ctr Head & Orthopaed, Ctr Rheumatol & Spine Dis, COPECARE, Kristiansand, Norway

[11] Univ Lisbon, Hosp Santa Maria, Ctr Acad Med Lisboa, Inst Med Mol,Fac Med,CHULN,Dept Rheumatol, Lisbon, Portugal

[12] Univ Aberdeen, Aberdeen Ctr Arthrit & Musculoskeletal Hlth, Epidemiol Grp, Aberdeen, Scotland

[13] Carol Davila Univ Med & Pharm, Bucharest, Romania

[14] Helsinki Univ Hosp, Inflammat Ctr, Dept Rheumatol, Helsinki, Finland

[15] Spanish Soc Rheumatol, Res Unit, Madrid, Spain

[16] Univ Ljubljana, Dept Rheumatol, Univ Med Ctr Ljubljana, Ljubljana, Slovenia

[17] Univ Ljubljana, Fac Med, Ljubljana, Slovenia

[18] Univ Hosp, Dept Rheumatol, Reykjavik, Iceland

[19] Radboud Univ Nijmegen Med Ctr, Dept Rheumatol, Nijmegen, Netherlands

[20] Karolinska Inst, Dept Med Solna, Stockholm, Sweden

[21] Aarhus Univ, Aarhus Univ Hosp, Dept Rheumatol, Aarhus, Denmark

[22] Aarhus Univ, Dept Clin Med, Aarhus, Denmark

[23] Inst Biostat & Anal Ltd, Brno, Czech Republic

[24] Marmara Univ, Dept Rheumatol, Sch Med, Istanbul, Turkiye

[25] Univ Bari, Rheumatol Unit, DETO, Bari, Italy

[26] Univ Zurich, Univ Hosp Zurich, Dept Rheumatol, Zurich, Switzerland

[27] Hosp Garcia Orta, Dept Rheumatol, Almada, Portugal

[28] Univ Med & Pharm, Ctr Rheumat Dis, Bucharest, Romania

[29] Hosp Clin Univ, Rheumatol Serv, Santiago De Compostela, Spain

[30] Univ Iceland, Landspitali Univ Hosp, Ctr Rheumatol Res, Reykjavik, Iceland

[31] Univ Iceland, Fac Med, Reykjavik, Iceland

[32] Vrije Univ Amsterdam Med Ctr, Dept Rheumatol, Amsterdam UMC, Amsterdam, Netherlands

[33] Copenhagen Univ Hosp, COPECARE, Ctr Rheumatol & Spine Dis, Ctr Head & Orthopaed, Glostrup, Denmark

[34] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

来源：

JOURNAL OF RHEUMATOLOGY | 2023年 / 50卷 / 08期

关键词：

axial spondyloarthritis; patient-reported outcome measures; tumor necrosis factor inhibitors; HEALTH-ASSESSMENT QUESTIONNAIRE; FACTOR-ALPHA INHIBITION; FUNCTIONAL INDEX BASFI; ANKYLOSING-SPONDYLITIS; RHEUMATOID-ARTHRITIS; REPORTED OUTCOMES; DISEASE-ACTIVITY; TREATMENT RESPONSE; GLOBAL ASSESSMENT; PSORIATIC-ARTHRITIS;

D O I：

10.3899/jrheum.220459

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor ( TNFi), to assess the proportion reaching PRO "remission" across registries and treatment series, and to compare patients registered to fulfill the modified New York (mNY) criteria for ankylosing spondylitis (AS) vs patients with nonradiographic axSpA (nr-axSpA). Methods. Fifteen European registries contributed PRO scores for pain, fatigue, patient global assessment (PtGA), Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Health Assessment Questionnaire (HAQ) from 19,498 patients with axSpA. Changes in PROs and PRO remission rates (definitions: <= 20 mm for pain, fatigue, PtGA, BASDAI, and BASFI; <= 0.5 for HAQ) were calculated at 6, 12, and 24 months of treatment. Results. Heterogeneity in baseline characteristics and outcomes between registries were observed. In pooled data, 6 months after the start of a first TNFi, pain score was reduced by approximately 60% (median at baseline/6/12/24 months: 65/25/20/20 mm) in patients on treatment. Similar patterns were observed for fatigue (68/32/30/25 mm), PtGA (66/29/21/20 mm), BASDAI (58/26/21/19 mm), BASFI (46/20/16/16 mm), and HAQ (0.8/0.4/0.2/0.2). Patients with AS (n = 3281) had a slightly better response than patients with nr-axSpA (n = 993). The Lund Efficacy Index (LUNDEX)-adjusted remission rates at 6 months for pain/fatigue/PtGA/BASDAI/BASFI/HAQ were 39%/30%/38%/34%/35%/48% for the AS cohort and 30%/21%/26%/24%/33%/47% for the nr-axSpA cohort. Better PRO responses were seen with a first TNFi compared to a second and third TNFi. Conclusion. Patients with axSpA starting a TNFi achieved high PRO remission rates, most pronounced in those fulfilling the mNY criteria and for the first TNFi.

引用

页码：1009 / 1019

页数：11

共 50 条

[1] Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO
[2] 2-F
[3] Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
Baraliakos, X.
Braun, J.
[J]. RMD OPEN, 2015, 1
[4] Real-World Anti-Tumor Necrosis Factor Treatment in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Cost-Effectiveness Based on Number Needed to Treat to Improve Health Assessment Questionnaire
Barra, Lillian
Pope, Janet E.
Payne, Michael
[J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (07) : 1421 - 1428
[5] Bruce B, 2003, J RHEUMATOL, V30, P167
[6] CALIN A, 1994, J RHEUMATOL, V21, P2281
[7] Canhao H, 2011, ACTA REUMATOL PORT, V36, P45
[8] Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature
Carlos Torre-Alonso, Juan
Queiro, Ruben
Comellas, Marta
Lizan, Luis
Blanch, Carles
[J]. PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 733 - 747
[9] Carmona L, 2014, CLIN EXP RHEUMATOL, V32, pS163
[10] Tumor Necrosis Factor α Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis Results From a Large Observational Cohort
Ciurea, Adrian
Scherer, Almut
Exer, Pascale
Bernhard, Juerg
Dudler, Jean
Beyeler, Brigitte
Kissling, Rudolf
Stekhoven, Daniel
Rufibach, Kaspar
Tamborrini, Giorgio
Weiss, Bettina
Mueller, Ruediger
Nissen, Michael J.
Michel, Beat A.
van der Heijde, Desiree
Dougados, Maxime
Boonen, Annelies
Weber, Ulrich
[J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3096 - 3106

← 1 2 3 4 5 →